Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Mitogenic activity, measured as 3H-thymidine incorporation by NIH 3T3 cells, following stimulation with platelet-rich-plasma-derived serum (PRS), platelet-poor-plasma-derived serum and platelet extract was studied in 14 patients with myeloproliferative disorders (MPD) and 7 normal subjects. Reduced mitogenic activity was found in PRS and platelet extract of patients with MPD, as compared to controls. The average levels of platelet-derived growth factor (PDGF) equivalents were as follows: 16.3 +/- 7.2 pg/10(6) platelets in controls, 6.2 +/- 2.2 pg/10(6) (p less than 0.05) platelets in patients with polycythaemia vera, 1.8 +/- 0.4 pg/10(6) (p less than 0.01) platelets in patients with idiopathic myelofibrosis and 4.0 +/- 0.8 pg/10(6) (p less than 0.05) platelets in patients with essential thrombocythaemia (Dunnett test). A reduction of intraplatelet levels of beta-thromboglobulin, although not statistically significant, was found in the same patients. No apparent relation was found between the amount of PDGF equivalents and the degree of bone marrow fibrosis.
Romano
M
M
Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italia.
Viero
P
P
Cortellazzo
S
S
Barbui
T
T
Donati
M B
MB
Poggi
A
A
D000328:Adult; D000368:Aged; D000818:Animals; D001792:Blood Platelets / Q000032:analysis; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000032:analysis* / Q000172:deficiency / Q000502:physiology; D055728:Primary Myelofibrosis / Q000209:etiology* / Q000473:pathology; D001620:beta-Thromboglobulin / Q000172:deficiency
D010982:Platelet-Derived Growth Factor; D001620:beta-Thromboglobulin